• Erasca, Inc. will participate in investor conferences and one-on-one investor meetings in September 2024.
• The company focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
• Management will participate in 22nd Annual Morgan Stanley Global Healthcare Conference and Cantor Global Healthcare Conference.
• The conference will take place at the InterContinental Barclay in New York.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings.
22nd Annual Morgan Stanley Global Healthcare Conference
Location: New York Marriott Marquis, New York, NY
Format: Fireside Chat
Date and Time: Thursday, September 5, 12:20 – 12:55 pm Eastern Time
2024 Cantor Global Healthcare Conference
Location: InterContinental Barclay, New York, NY
Format: Fireside Chat
Date and Time: Wednesday, September 18, 3:40 – 4:10 pm Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.68 |
| Daily Change: | -0.03 -1.11 |
| Daily Volume: | 1,435,162 |
| Market Cap: | US$757.100M |
September 25, 2024 June 18, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
